Chai Gadde

Chai Gadde serves as CEO at BioTek reMEDys. BioTek reMEDys operates in the pharmaceuticals sector with approximately 99.0 employees. The company is headquartered in Philadelphia, Pennsylvania. BioTek reMEDys generates annual revenue of 6000000.0.

Industry & Role Insights

• • MessageCEO tracks 1,288 executives in the pharmaceuticals sector.
• • 2,637 executive contacts are available in Pennsylvania.
• • Our database includes 201,465 c suite-level executives.

DNS Made Easy Outlook Microsoft Office 365 Salesforce Barracuda Networks Google Font API WordPress.org Mobile Friendly Google Maps Remote AI

ivig home infusion hemophilia specialty pharmacy pharmaceutical manufacturing infusion services immunoglobulin therapy supply chain management patient management program bleeding disorders pidd chronic conditions specialty medications biologics biotherapeutics drug administration patient adherence pharmacist support treatment coordination therapy management patient education disease management clinical monitoring medication authorization patient advocacy healthcare providers insurer coordination cost-effective treatment quality of care patient satisfaction disease support programs chronic inflammatory demyelinating polyneuropathy dermatomyositis guillain-barre syndrome myasthenia gravis polymyositis von willebrand disease idiopathic thrombocytopenic purpura congenital hypogammaglobinemia common variable immunodeficiency primary immunodeficiency medical assistance treatment solutions innovative technology healthcare solutions nursing network clinical care patient-centered care administration support in-home care pharmaceuticals medical logistics & supply chain

YM

Yathendra Madineni Chief Executive Officer at 4C Pharma Solutions

RB

Ronan Brown Chief Operating Officer at 4G Clinical

HK

Hitoshi Kamiya Chief Executive Officer at A2 Healthcare Corporation

LJ

Lars Jensen CEO at A-apoteket

TL

Tien Lee CEO at Aardvark Therapeutics, Inc.

Outreach Guidance — pharmaceuticals Sector

Executives like Chai Gadde in the pharmaceuticals sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at BioTek reMEDys.

Chai Gadde's Position in the MessageCEO Database

• •Chai Gadde is 1 of 1 verified executive contact we track at BioTek reMEDys.
• •1,240 verified executive contacts in pharmaceuticals are in the MessageCEO database.
• •2,484 verified executive contacts in Pennsylvania are in the database.
• •4 verified contacts work at pharmaceuticals companies in the 99.0 employee range (same size as BioTek reMEDys).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated October 2026.

How do I reach Chai Gadde directly?

Chai Gadde's verified email address is available to MessageCEO Pro subscribers. They currently serve as CEO at BioTek reMEDys. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Chai Gadde work for?

Chai Gadde is CEO at BioTek reMEDys, a company in the pharmaceuticals sector with 99.0 employees. The company is based in Philadelphia, Pennsylvania.

Can I pitch or sell to Chai Gadde?

As CEO at BioTek reMEDys, Chai Gadde is a key decision-maker in the pharmaceuticals sector. MessageCEO Pro gives you verified email to reach Chai Gadde directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Chai Gadde in?

Chai Gadde works in the pharmaceuticals industry as CEO at BioTek reMEDys. MessageCEO provides verified contact information for executives across all major industries.

Is Chai Gadde's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Chai Gadde's profile is kept up-to-date with the latest available information.

Last updated: October 9, 2026